CGEM Company Profile and Key Details

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) closed at $10.34 USD, gaining $0.66 (6.82%) from the previous close of $9.68. The stock is currently mid-range between its 52-week high and low $5.68 and $13.33. With a market capitalization of about $610.84 million, Cullinan Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.10). Key stats such as the average daily volume over the past year has been around 1.27 million shares, in line with its 52-week average. Headquartered in Cambridge, MA, Cullinan Therapeutics, Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Nadim Ahmed, the company employs approximately 111 people and listed since January 08, 2021. Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies.

Cullinan Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.50. This means the shares are trading above this model’s fair value.

Short-term trend indicators are bearishly aligned (SMA20 -7.11%, SMA50 10.95%, SMA200 27.7%). The stock’s 14-day RSI is 50.56 (neutral), while the ATR of 0.93 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.43% below its high and over 82.04% above its low. Average 10-day trading volume of 1.26 million shares is in line with the 3-month average of 1.24 million, indicating normal recent market interest.

Cullinan Therapeutics, Inc. generated EPS of -$3.68 over the past year. Five-year average earnings growth is -45.66%. Wall Street analysts project EPS growth of 1.64% annually over the next five years. The latest quarter delivered EPS of -$0.77. The next quarter is forecast at -$0.78. Next year's EPS is expected at -$0.61. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $38.00 to $24.00. The high target offers 267.5% upside. The low target suggests 132.11% downside. The mean target is $30.70. This offers 196.91% upside. Cullinan Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -18.95%. The prior quarter beat by 28.92%. Over the last six quarters, Apple has recorded several small beats. These include 2.74% in August 08, 2024.

Cullinan Therapeutics, Inc. has 59.07 million shares outstanding. The public float is 36.05 million shares, elevated short interest at 12.23% of float. This equals 6.24 million shares. The short ratio is 16.28 days. Institutional investors hold 112.71% of the float. Insiders own 4.54%. Lynx1 Capital Management LP holds 8.96 million shares, UBS Oncology Impact Fund L.P. has 7.65 million shares and LAMPERT MARK N has 4.06 million shares. Over the past six months, insider transactions show net buying. They sold 18.15 thousand shares across 6 transactions.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) shares are down -15.11% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cullinan Therapeutics, Inc. trading at a premium to the broader market with a P/E of -2.79. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $36.03, suggesting 248.45% upside. Our AI forecast model points to short-term strength (7.16% over two weeks), a medium-term rise (170.12% over three months), and a longer-term gain (113.06% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cullinan Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.16%, with price expected at $11.08 by January 02, 2026, within a range of $9.75 to $12.40 3-Month Outlook: Projected rise of 170.12%, reaching $27.93 by March 19, 2026, with a range of $25.79 to $29.62. 1-Year Outlook: Projected gain of 113.06%, with price at $22.03 by December 18, 2026, within a range of $12.11 to $31.39.

Cullinan Therapeutics, Inc. trades at a P/E ratio of -2.79, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.34 suggesting the stock is closer to book value. The P/FCF stands at -3.48, also above market averages.